anonymised and aggregated data on the management of patients with rheumatoid arthritis (Lallemand inc)
90
Structured Review
Lallemand inc
anonymised and aggregated data on the management of patients with rheumatoid arthritis

Anonymised And Aggregated Data On The Management Of Patients With Rheumatoid Arthritis, supplied by Lallemand inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+anonymisation/anonymised+and+aggregated+data+on+the+management+of+patients+with+rheumatoid+arthritis/pmc06451627-249-26-6
Average 90 stars, based on 1 article reviews

Anonymised And Aggregated Data On The Management Of Patients With Rheumatoid Arthritis, supplied by Lallemand inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+anonymisation/anonymised+and+aggregated+data+on+the+management+of+patients+with+rheumatoid+arthritis/pmc06451627-249-26-6
Average 90 stars, based on 1 article reviews
anonymised and aggregated data on the management of patients with rheumatoid arthritis - by Bioz Stars,
2026-11
90/100 stars
Images
1) Product Images from "Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?"
Article Title: Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?
Journal: European Journal of Hospital Pharmacy. Science and Practice
doi: 10.1136/ejhpharm-2016-000904
Figure Legend Snippet: Annual average costs for biotherapy acquisition and care for a rheumatoid arthritis patient with adalimumab, etanercept, originator infliximab or biosimilar infliximab: 2012 and 2015 calculated costs (data from the Alsace population 24 )
Techniques Used:
Figure Legend Snippet: Estimated annual budget savings attributable to the introduction of biosimilar infliximab for the treatment of adult rheumatoid arthritis patients, according to three different scenarios
Techniques Used:
Figure Legend Snippet: Additional rheumatoid arthritis patients who could be treated for 1 year if the savings were spent on biosimilar infliximab
Techniques Used:
Related Articles
other:Article Title: Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings? Article Snippet: The authors are grateful to |